Headlands Technologies LLC Makes New $1.04 Million Investment in Maravai LifeSciences Holdings, Inc. $MRVI

Key Points

• Headlands Technologies purchased 166,327 Maravai LifeSciences shares worth approximately $1.04 million, giving it a 0.06% stake. Institutional investors collectively own 50.25% of the company.
• Maravai reported quarterly revenue of $51.44 million and an adjusted loss of $0.02 per share, beating analyst estimates for both measures, though it continues to post negative profitability metrics.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and a $6.25 target price; the stock recently traded at $7.30 after falling 4.5%, while an insider sold 25,000 shares under a pre-arranged trading plan.

Headlands Technologies LLC purchased a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 166,327 shares of the company's stock, valued at approximately $1,038,000. Headlands Technologies LLC owned 0.06% of Maravai LifeSciences at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in MRVI. Royal Bank of Canada lifted its holdings in Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company's stock worth $27,000 after purchasing an additional 3,209 shares in the last quarter. Quantessence Capital LLC purchased a new position in Maravai LifeSciences during the 3rd quarter valued at about $31,000. Abel Hall LLC purchased a new position in Maravai LifeSciences during the 3rd quarter valued at about $33,000. CIBC Bancorp USA Inc. bought a new stake in shares of Maravai LifeSciences during the third quarter valued at about $33,000. Finally, Virtu Financial LLC bought a new stake in shares of Maravai LifeSciences during the fourth quarter valued at about $34,000. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $5.06, for a total transaction of $126,500.00. Following the sale, the general counsel directly owned 360,767 shares in the company, valued at approximately $1,825,481.02. This trade represents a 6.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company's stock.

Maravai LifeSciences Trading Down 4.5%

NASDAQ MRVI opened at $7.30 on Wednesday. Maravai LifeSciences Holdings, Inc. has a 12 month low of $2.29 and a 12 month high of $9.42. The company has a current ratio of 4.05, a quick ratio of 2.98 and a debt-to-equity ratio of 0.49. The stock's fifty day moving average price is $6.70 and its 200-day moving average price is $4.83. The stock has a market cap of $1.90 billion, a P/E ratio of -14.04 and a beta of 0.60.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The business had revenue of $51.44 million during the quarter, compared to analysts' expectations of $48.67 million. As a group, equities analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MRVI. Weiss Ratings restated a "sell (d-)" rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a $6.00 target price on shares of Maravai LifeSciences in a research note on Friday, May 8th. UBS Group reissued a "reduce" rating on shares of Maravai LifeSciences in a report on Wednesday, June 3rd. Wall Street Zen lowered shares of Maravai LifeSciences from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Wells Fargo & Company upped their target price on Maravai LifeSciences from $5.50 to $6.50 and gave the stock an "overweight" rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $6.25.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc NASDAQ: MRVI is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company's offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai's platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.

Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source